RxSight, Inc.

RxSight, Inc.

RXST·NASDAQ

$4.79

-2.3%
HealthcareMedical - Devices

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

At a Glance

Live Snapshot
Market Cap$198.29M
EPS-0.9500
P/E Ratio-5.04
Earnings Date08/06/2026

rxst

Other Current Liabilities

Last Annual Value

19.80M

3-Year CAGR

22%

5-Year CAGR

18%

10-Year CAGR

15%

RxSight, Inc.

RxSight, Inc. Competitors Analysis of Other Current Liabilities

RXST · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
RXST logo
RxSight, Inc.
NASDAQ:RXST
19.80M
97.8%23.4%N/A 
16.64M
31.1%52.2%28.2%
30.09M
36.2%12.3%N/A
32.79M
94.2%38.0%14.1%
3.90M
23.0%49.4%18.7%
25.27M
28.8%6.4%19.9%
8.19M
61.8%27.7%-9.1%
SRDX logo
Surmodics, Inc.
NASDAQ:SRDX
13.85M
35.5%25.9%16.9%
23.91M
-0.5%N/AN/A
3.54M
66.6%N/A43.2%
NPCE logo
NeuroPace, Inc.
NASDAQ:NPCE
13.34M
N/A93.6%N/A
RxSight, Inc.

RxSight, Inc. Fair Value Envelope

RXST · NASDAQ

Our analysis suggests that RXST has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.79, this represents a potential HIDDEN relative to our calculated worth for RxSight, Inc..

Intrinsic Value
Current Price: $4.79